摘要:
1,4 Di-substituted piperidine muscarinic antagonists of formula I ##STR1## or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein X is a bond, --O--, --SO.sub.0-2 --, --CO--, --C(OR.sup.7).sub.2 --, --CH.sub.2 --O--, --O--CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 --, --CH(C.sub.1 --C.sub.6 alkyl)--, --C(C.sub.1 --C.sub.6 alkyl).sub.2 --, --CONR.sup.17 --, --NR.sup.17 CO--, --SO.sub.2 NR.sup.17 -- or --NR.sup.17 SO.sub.2 --; R is C.sub.3 --C.sub.6 cycloalkyl, optionally substituted phenyl or optionally substituted pyridyl; R.sup.1 is H, --CN, --CF.sub.3, alkyl, cycloalkyl, cycloalkenyl, alkenyl, --COR.sup.15, --COO(alkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl), alkylaryl, alkylheteroaryl or --CON(R.sup.13).sub.2 ; R.sup.2 is cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted 4-piperidinyl; and R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.13, R.sup.15 and R.sup.17 are as defined in the specification are disclosed as being useful for treating cognitive disorders such as Alzheimer's disease; also disclosed are pharmaceutical compositions, methods of preparation and combinations of compounds of formula I capable of enhancing ACh release with ACh'ase inhibitors.
摘要翻译:1,4-二取代的式I的哌啶毒蕈碱拮抗剂或其药学上可接受的盐,酯或溶剂化物,其中X为-O-,-SO 2 - , - CO - , - C(OR 7)2 - , - CH 2 -CH 2 - , - CH = CH - , - CH 2 - , - CH(C 1 -C 6烷基) - , - (C 1 -C 6烷基) NR 17 CO - , - SO 2 NR 17 - 或-NR 17 SO 2 - ; R为C 3 -C 6环烷基,任选取代的苯基或任选取代的吡啶基; R 1是H,-CN,-CF 3,烷基,环烷基,环烯基,烯基,-COR 15,-COO(烷基,芳基,杂芳基,烷基芳基或烷基杂芳基),烷基芳基,烷基杂芳基或-CON(R 13) R2是环烷基,环烯基,叔丁氧基羰基或任选取代的4-哌啶基; R 3,R 4,R 5,R 6,R 7,R 13,R 15和R 17如本说明书中所定义,可用于治疗认知障碍如阿尔茨海默病; 还公开了能够与ACh酶抑制剂一起增强ACh释放的药物组合物,制备方法和式I化合物的组合。
摘要:
Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
摘要:
Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
摘要:
17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R4)(R6)Y are oriented cis to each other; W represents O or S; R1 represents —H or optionally substituted —(C1-C4)alkyl; n represents 0 or an integer of 1-3; and R2 represents any of a variety of substituents on ring A. R4 generally represents —H but may be a bond terminating at the ortho position of ring A. Y represents fluorine, —OR5, or —SR5, and R5 represents —H, optionally substituted —(C1-C4)alkyl, optionally substituted -phenyl, optionally substituted —(C1-C4)alkyl-phenyl, or optionally substituted —(C1-C4)acyl. R6 represents any of a variety of groups as defined in the specification and claims, including heteroaryl, arylalkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkynyl, arylalkynyl, heteroarylalkynyl, aryl, and indolyl. Pharmaceutically acceptable salts and N-oxides of these materials are also included. Also claimed are pharmaceutical compositions containing these materials and methods of using them.
摘要:
Di-N-substituted piperazine or 1,4-di-substituted piperidine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein Q, n, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations with acetyl-cholinesterase inhibitors of compounds capable of enhancing acetylcholine release and having the above formula.
摘要:
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
摘要:
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
摘要:
Disclosed are substituted indoles, pharmaceutical compositions containing such indoles, and their use in treating or preventing PPAR-&ggr; mediated diseases or conditions, such as osteopenia, osteoporosis, cancer, diabetes and atherosclerosis.
摘要:
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.
摘要:
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.